StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Bimatoprost

HCID 5311027
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
155206-00-1
Standard-SMILES
CCNC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O
InChIKey
AQOKCDNYWBIDND-FTOWTWDKSA-N
Summenformel
C25H37NO4
Durchschnittliche Molmasse
415,6 g/mol
Monoisotopische Masse
415,27225866

Überblick

Bimatoprost is a monocarboxylic acid amide. It has a role as an antihypertensive agent and an antiglaucoma drug.

Namen und Bezeichner

Bevorzugter Name
Bimatoprost
IUPAC
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
Englischer Name
Bimatoprost
Summenformel
C25H37NO4
Molmasse
415.57

Namen und Synonyme

Bimatoprost155206-00-1LumiganLatisseAGN 192024ProstamideAGN-192024bimatoprostum(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamideDURYSTAQXS94885MZ(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide
Weitere Namen anzeigen
Bimabimatoprost powderN-ETHYL-9ALPHA,11ALPHA,15S-TRIHYDROXY-17-PHENYL-18,19,20-TRINOR-PROSTA-5Z, 13E-DIEN-1-AMIDEbimatoprosBimatoprost (W.S)BiMatoprost HOUSE STANDARD17-phenyl-tri-norprostaglandin f2α-ethyl amide17-PHENYL TRINOR PROSTAGLANDIN F2ALPHA ETHYL AMIDE
CHEBI:51230DTXSID30895042GANFORT COMPONENT BIMATOPROSTAGN1920245-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-(1alpha(Z),2beta(1E,3S*),3alpha,5alpha))-(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl]-N-ethylhept-5-enamide(5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl}-N-ethylhept-5-enamide192024, AGN

Datenbank-Bezeichner

CAS
155206-00-1
PubChem CID
5311027
DTXSID
DTXSID30895042
ChEMBL
CHEMBL1200963
ChEBI
CHEBI:51230
UNII
QXS94885MZ
EC Number
642-890-9
Nikkaji
J1.596.089B

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
2,8
Polarare Oberfläche (TPSA)
89,8 Ų
H-Brücken-Donoren
4
H-Brücken-Akzeptoren
4
Frei drehbare Bindungen
12
Schwere Atome
30
Formalladung
0
Komplexität
541

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
LogP3.2
Solubility · 2 Einträge

soluble in water

1.87e-02 g/L

Human Drugs · 4 Einträge

Breast Feeding; Lactation; Milk, Human; Antiglaucoma Agents; Prostaglandins

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Melting Point63-67
Physical DescriptionSolid
Dissociation Constants14.3, - 0.23

Physikochemische Eigenschaften

Schmelzpunkt
66 · 66-68°C
Siedepunkt
629.8 · 629.8±55.0 °C(Predicted)
Dichte
1.145 · 1.145±0.06 g/cm3(Predicted)
storage temp.
-20 °C · -20°C
Löslichkeit
Chloroform (Slightly), Dichloromethane (Slightly), Methanol (Slightly)
Aggregatzustand
solid
pka
14.25 · 14.25±0.20(Predicted)
Farbe
White to Off-White
BCS Class
3 · 3
Stabilität
Light Sensitive
Kosmetik-Inhaltsstoffe Funktionen
EYELASH CONDITIONING
InChIKey
AQOKCDNYWBIDND-FTOWTWDKSA-N
SMILES
C(NCC)(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=CC=C1
CAS Datenbank
155206 · 155206-00-1(CAS DataBase Reference)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H302 (23.8%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P264, P264+P265, P270, P280, P301+P317, P302+P352, P305+P351+P338, P317, P318, P321, P330, P337+P317, P362+P364, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 21 reports by companies from 12 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Hazard Classes and CategoriesAcute Tox. 4 (23.8%)

Toxikologische Informationen

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

wgk
3
Speicherklasse
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
Acute Tox. 4 OralRepr. 1B

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

S01EE03

S - Sensory organs

QS - Sensory organs

Protein BindingBimatoprost is about 88%-90% bound to plasma proteins.
Pharmacodynamics · 1 Eintrag

High intraocular pressure is a major risk factor for glaucoma-related visual field loss. A linear relationship exists between intraocular pressure and the risk of damaging the optic nerve, which can lead to considerable visual impairment. Therefore, conditions such as ocular hypertension and glaucoma can cause dangerous elevations of intraocular pressure. Bimatoprost rapidly decreases intraocular pressure and reduces the risk for visual field loss from ocular hypertension due to various causes. Other effects of this drug may include gradual changes in eyelid pigmentation, changes in iris pigmentation, changes in eyelash pigmentation, growth and thickness. Patients should be informed of these possible effects, especially if this drug is only administered to one eye, which may noticeably change in appearance with bimatoprost treatment.

Mechanism of Action · 1 Eintrag

Bimatoprost imitates the effects of prostamides, specifically prostaglandin F2α. Bimatoprost mildly stimulates aqueous humor outflow, relieving elevated intraocular pressure and decreasing the risk of optic nerve damage. It is thought that bimatoprost reduces intraocular pressure (IOP) in humans by causing an increase in outflow of the aqueous humor via the trabecular meshwork and uveoscleral pathways. It achieves the above effects by decreasing tonographic resistance to aqueous humor outflow. Bimatoprost does not affect aqueous humor production.

Biological Half-LifeThe elimination half-life of bimatoprost is approximately 45 minutes.
Metabolism/Metabolites · 1 Eintrag

Bimatoprost is hydrolyzed to its active form, bimatoprost acid, in the eye. Bimatoprost undergoes oxidation, N-deethylation, and glucuronidation after it is systemically absorbed, and this leads to the production of various metabolites. In vitro studies show that CYP3A4 is an enzyme that participates in the metabolism of bimatoprost. Despite this, many enzymes and pathways metabolize bimatoprost, therefore, no significant drug-drug interactions are likely to occur. Glucuronidated metabolites comprise most of the excreted drug product in the blood, urine, and feces in rats.

FDA Pharmacological Classification · 6 Einträge

QXS94885MZ

BIMATOPROST

Established Pharmacologic Class [EPC] - Prostaglandin Analog

Chemical Structure [CS] - Prostaglandins

Bimatoprost is a Prostaglandin Analog.

BIMATOPROST

MeSH Pharmacological Classification · 1 Eintrag

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Absorption, Distribution and Excretion · 4 Einträge

This drug is absorbed systemically when administered to the eye. A study was performed on 15 healthy volunteers and bimatoprost ophthalmic solution 0.03% was administered once daily for 14 days. The mean Cmax was approximately 0.08 ng/mL and AUC0-24hr was approximately 0.09 on days 7 and 14 of the study. By 10 minutes, peak blood concentration was achieved. Bimatoprost was not detectable at 1.5 hours after administration in most subjects. The maximum blood concentration in a study of 6 healthy volunteers was determined to be 12.2 ng/mL. Steady state was reached in the first week of dosing. One drug label mentions that onset of decreased intraocular pressure occurs approximately 4 hours after the first administration and the peak effect occurs in the range of 8-12 hours. Bimatoprost effects may last up to 24 hours.

One pharmacokinetic study of bimatoprost in 6 healthy volunteers determined that 67% of the administered dose was found to be excreted in the urine while 25% of the dose was recovered in the feces.

The volume of distribution at steady state is 0.67 L/kg.. It penetrates the human cornea and sclera.

The clearance was measured to be 1.5 L/hr/kg in healthy subjects receiving IV administration of bimatoprost dosed at 3.12 ug/kg.

Cellular LocationsCytoplasm
Anwendungen · 2 Einträge

BeschreibungBimatoprost was first introduced in the US and Brazil as Lumigan, an ophthalmic solution (0.03%) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, a proven risk of glaucomatous visual field loss. Bitamoprost is a new agent belonging to the PGF2α analog class of prostamides launched in this indication after latanoprost, the most efficaceous topical medication currently available. This synthetic fatty acid amide can be prepared by esterification of 17- phenyl-18,19,20-trinorprostaglandin F2α followed by ethylamidation. Bimatoprost, as related prostamides, is devoid of typical activities associated with PGF2,, analogs; it exhibits a unique pharmacological profile in contracting the feline iris sphincter with an EC50 of 34 nM without interacting with any known prostanoid receptors. Thus it mimics the action of endogenous prostamides on specific receptors that lower IOP by increasing aqueous humor outflow through both pressure-insensitive and pressure-sensitive pathways without reducing humor formation. In a 3-month controlled clinical trial of efficacy and safety in patients with elevated IOP, bimatoprost demonstrated lower mean intraocular pressures at every time point throughout the study, as well as a good tolerance and systemic safety profile compared to latanoprost.

VerwendenBimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. It reduces intraocular pressure (IOP) by increasing the outflow of aqueous fluid from the eyes. It ha

Vor- und nachgelagerte Produkte

Nachgelagerte Produkte

(5E)-BiMatoprost

Zugehörige Reaktionen

9
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 62567
HRID 62567als Edukt
Reaktionsgleichung von HRID 422890
HRID 422890als Edukt
Reaktionsgleichung von HRID 517405
HRID 517405als Produkt
Reaktionsgleichung von HRID 551520
HRID 551520als Edukt
Reaktionsgleichung von HRID 591123
HRID 591123als Edukt
Reaktionsgleichung von HRID 593414
HRID 593414als Produkt
Reaktionsgleichung von HRID 1621277
HRID 1621277als Produkt
Reaktionsgleichung von HRID 1621278
HRID 1621278als Produkt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung